» Articles » PMID: 35169897

Radiogenomic Association Between the T2-FLAIR Mismatch Sign and IDH Mutation Status in Adult Patients with Lower-grade Gliomas: an Updated Systematic Review and Meta-analysis

Overview
Journal Eur Radiol
Specialty Radiology
Date 2022 Feb 16
PMID 35169897
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To reveal a radiogenomic correlation between the presence of the T2-fluid-attenuated inversion recovery resection (T2-FLAIR) mismatch sign on MR images and isocitrate dehydrogenase (IDH) mutation status in adult patients with lower-grade gliomas (LGGs).

Methods: A web-based systemic search for eligible literature up to April 13, 2021, was conducted on PubMed, Embase, and the Cochrane Library databases by two independent reviewers. This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. We included studies evaluating the accuracy of the T2-FLAIR mismatch sign in diagnosing the IDH mutation in adult patients with LGGs. The T2-FLAIR mismatch sign was defined as a T2-hyperintense lesion that is hypointense on FLAIR except for a hyperintense rim.

Results: Fourteen studies (n = 1986) were finally identified. The mean age of patients in the included studies ranged from 38.5 to 56 years. The pooled area under the curve (AUC), sensitivity, and specificity were obtained for each molecular profile: IDHmut-Codel: 0.46 (95% confidence interval [CI]: 0.42-0.50), 1% (95%CI: 0-7%), and 69% (95%CI: 62-75%), respectively; IDHmut-Noncodel: 0.75 (95%CI: 0.71-0.79), 42% (95%CI: 34-50%), and 99% (95%CI: 96-100%), respectively; IDH-Mutation regardless of 1p/19q codeletion status: 0.77 (95%CI: 0.73-0.80), 29% (95%CI: 21-40%), and 99% (95%CI: 92-100%), respectively.

Conclusions: The T2-FLAIR mismatch sign was an insensitive but highly specific marker for IDHmut-Noncodel and IDH-Mutation LGGs, whereas it was not a useful marker for IDHmut-Codel LGGs. The findings might identify the T2-FLAIR mismatch sign as a non-invasive imaging biomarker for the selection of patients with IDH-mutant LGGs.

Key Points: • The T2-FLAIR mismatch sign was not a sensitive sign for IDH mutation in LGGs. • The T2-FLAIR mismatch sign was related to IDHmut-Noncodel with a specificity of 99%. • The pooled specificity (69%) of the T2-FLAIR mismatch sign for IDHmut-Codel was low.

Citing Articles

Preoperative prediction of diffuse glioma type and grade in adults: a gadolinium-free MRI-based decision tree.

Azizova A, Prysiazhniuk Y, Wamelink I, Cakmak M, Kaya E, Wesseling P Eur Radiol. 2024; 35(3):1242-1254.

PMID: 39425768 PMC: 11836213. DOI: 10.1007/s00330-024-11140-5.


Usefulness of synthetic MRI for differentiation of IDH-mutant diffuse gliomas and its comparison with the T2-FLAIR mismatch sign.

Onishi S, Yamasaki F, Akiyama Y, Kawahara D, Amatya V, Yonezawa U J Neurooncol. 2024; 170(2):429-436.

PMID: 39133381 PMC: 11538156. DOI: 10.1007/s11060-024-04794-0.


T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant.

Onishi S, Kojima M, Yamasaki F, Amatya V, Yonezawa U, Taguchi A Neurosurg Rev. 2024; 47(1):412.

PMID: 39117984 PMC: 11310237. DOI: 10.1007/s10143-024-02632-5.


T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.

Lee M, Jain R, Galbraith K, Chen A, Lieberman E, Patel S Clin Cancer Res. 2024; 30(16):3512-3519.

PMID: 38829583 PMC: 11326959. DOI: 10.1158/1078-0432.CCR-24-0311.


Identifying IDH-mutant and 1p/19q noncodeleted astrocytomas from nonenhancing gliomas: Manual recognition followed by artificial intelligence recognition.

He L, Zhang H, Li T, Yang J, Zhou Y, Wang J Neurooncol Adv. 2024; 6(1):vdae013.

PMID: 38405203 PMC: 10894653. DOI: 10.1093/noajnl/vdae013.


References
1.
Batchala P, Muttikkal T, Donahue J, Patrie J, Schiff D, Fadul C . Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in -Mutant Lower Grade Gliomas. AJNR Am J Neuroradiol. 2019; 40(3):426-432. PMC: 7028667. DOI: 10.3174/ajnr.A5957. View